课题基金 / 基金详情

TAS::75 0849::TAS IN THIS PHASE I SBIR THE BREAST CANCER ADENOCARCINOMA CELL LI

TAS::75 0849::TAS 在这一阶段 I SBIR 乳腺癌腺癌细胞 LI

批准号：

8164743

负责人：

SHAHARYAR KHAN

金额：

$19.62万

依托单位：

GENCIA CORPORATION

依托单位国家：

美国

项目类别：

财政年份：

2010

资助国家：

美国

项目状态：

已结题

起止时间：

2010-09-30 至 2011-06-30

来源：

https://reporter.nih.gov/project-details/8164743

关键词：

Adenocarcinoma Adenocarcinoma Cell Apoptosis Apoptotic Bioenergetics Cell Line Cell Proliferation Collection Complex Dose Functional disorder Glycolysis Human MCF7 cell Measures Membrane Potentials Mitochondria Mitochondrial DNA Mutate Neoplasm Metastasis Neoplasms Oxidative Phosphorylation Pathway interactions Phase Recombinants Research Resistance SCID Mice Small Business Innovation Research Grant TP53 gene Tumor Volume Warburg Effect Xenograft procedure glucose output indexing malignant breast neoplasm mitochondrial membrane mtTF1 transcription factor response tumor

项目摘要

项目成果

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

Bioenergetic dysfunction is a well- recognized feature of most (<97%) metastasizing tumors. Dysfunction of major cell proliferation controllers mutated in the majority of neoplasms, such as the p53, Ras, Myc, PI3K/Akt pathways, results in suppression of mitochondrial oxidative phosphorylation (OXPHOS) and in activation of glycolysis, known as the Warburg effect, which contributes to the resistance to apoptosis. Gencia has developed a recombinant form of human TFAM, the mitochondrial transcription factor A (rhTFAM), modified to allow it to traverse cellular barriers and to be specifically imported into the mitochondria.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文